Regeneron Careers in New York, NY

Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008. In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection. We have subsequently received approval from the FDA for three additional indications. In 2015, PRALUENT® (alirocumab) Injection became the first approved PCSK9 inhibitor in the U.S. We are a leader in human antibody technologies and have built a pipeline of antibody drug candidates against both novel and validated drug targets in diseases ranging from cancer to rheumatoid arthritis. Our strategic antibody and immuno-oncology collaborations with Sanofi provide committed long-term funding and expertise to supplement our own. Our business is creating and commercializing new medicines for patients – at Regeneron our business is your health.